CSI Market
Sign In | Register

Procept Biorobotics (PRCT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PRCT quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Procept Biorobotics balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-95.57
Depreciation & amortization6.39
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.22
Inventories Decrease /-Increase-13.93
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation47.60
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.16
Fair Value Adjustment Of Warrants And Gain Loss On Derivative Instruments Net Pretax-
Non Cash Lease Accretion Expense-0.51
Transfer From Inventory To Property And Equipment Net-
Capital Expenditures Incurred But Not Yet Paid0.97
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Conversion Of Stock Amount Converted-
Increase Decrease In Line Of Credit Facility Liability-
Increase Decrease In Contract With Customer Liability3.31
Foreign Currency Transaction Gain Loss Realized After Tax-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.90
Increase (Decrease) in Accounts Payable6.65
Accrued Expense1.73
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.10
Other Working Capital-1.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.97
Discontinued operations0.00
Net Cash flow from Operating Activities-48.99
Investing Activities
Capital Expenditures-9.36
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-9.36
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.83
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-330.40
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents336.76
Payment For Debt Extinguishment Or Debt Prepayment Cost Final Payment Fee-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities11.19
Effect of exchange rate on cash flow-0.07
Discontinued operations0.00
Free Cash Flow-58.34
Total Cash Flow-47.22
4 historic quarters locked

Sign in to unlock the full Procept Biorobotics cash flow history.

Sign In Create Free Account

About Procept Biorobotics Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: prct-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001588978-26-000009

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document